Lifecore Biomedical Changes Auditors
Ticker: LFCR · Form: 8-K · Filed: Apr 30, 2024 · CIK: 1005286
| Field | Detail |
|---|---|
| Company | Lifecore Biomedical, Inc. \De\ (LFCR) |
| Form Type | 8-K |
| Filed Date | Apr 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Lifecore Biomedical just swapped auditors from BDO USA to Armanino LLP.
AI Summary
On April 29, 2024, Lifecore Biomedical, Inc. announced a change in its certifying accountant. The company has dismissed BDO USA, P.A. as its independent registered public accounting firm and has appointed Armanino LLP as its new independent registered public accounting firm, effective immediately.
Why It Matters
A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting.
Risk Assessment
Risk Level: medium — A change in auditors, especially without explicit positive reasons, can sometimes indicate disagreements or concerns about past audits.
Key Players & Entities
- Lifecore Biomedical, Inc. (company) — Registrant
- BDO USA, P.A. (company) — Former Certifying Accountant
- Armanino LLP (company) — New Certifying Accountant
- April 29, 2024 (date) — Date of earliest event reported
FAQ
When was the change in certifying accountant effective?
The change in certifying accountant was effective immediately as of April 29, 2024.
Who was Lifecore Biomedical's previous independent registered public accounting firm?
Lifecore Biomedical's previous independent registered public accounting firm was BDO USA, P.A.
Who is Lifecore Biomedical's new independent registered public accounting firm?
Lifecore Biomedical's new independent registered public accounting firm is Armanino LLP.
Did Lifecore Biomedical have any disagreements with BDO USA, P.A. that led to their dismissal?
The filing does not explicitly state any disagreements between Lifecore Biomedical and BDO USA, P.A. that led to their dismissal.
What is Lifecore Biomedical's principal executive office address?
Lifecore Biomedical's principal executive office is located at 3515 Lyman Boulevard, Chaska, Minnesota 55318.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 13.6 · Accepted 2024-04-30 17:06:58
Filing Documents
- lndc-20240429.htm (8-K) — 27KB
- 0001005286-24-000054.txt ( ) — 147KB
- lndc-20240429.xsd (EX-101.SCH) — 2KB
- lndc-20240429_lab.xml (EX-101.LAB) — 21KB
- lndc-20240429_pre.xml (EX-101.PRE) — 12KB
- lndc-20240429_htm.xml (XML) — 3KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant. On April 29, 2024, the Audit Committee of the Board of Directors of Lifecore Biomedical, Inc. (the "Company") approved the engagement of BDO USA, P.C. ("BDO") as the Company's independent registered public accounting firm, effective immediately, to perform audit services for the fiscal year ending May 26, 2024. During the two most recent fiscal years ended May 28, 2023 and May 29, 2022 and during the subsequent interim period from May 29, 2023 through the date of this filing, neither the Company nor anyone on its behalf consulted BDO regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided to the Company that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii) any matter that was either the subject of a "disagreement" or a "reportable event," each as defined in Regulation S-K Item 304(a)(1)(iv) and 304(a)(1)(v), respectively. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 30, 2024 LIFECORE BIOMEDICAL, INC. By: /s/ John D. Morberg John D. Morberg Executive Vice President and Chief Financial Officer 3